Literature DB >> 24827490

Successful treatment of severe lung hemorrhage caused by acquired factor V inhibitor with rituximab.

Yuji Yamada1, Yoshitaka Miyakawa, Mitsuaki Sawano, Yutaka Okano.   

Abstract

Acquired coagulation factor deficiency is a rare disorder that occurs in patients with drug reactions, malignancy and collagen diseases as well as during pregnancy. Most cases are caused by factor VIII inhibitors. We herein describe the case of a 61-year-old Japanese man with acquired factor V inhibitor who developed symptoms 11 days after lung surgery for empyema. The patient required mechanical ventilation to treat acute respiratory failure due to severe pulmonary hemorrhage. He responded poorly to steroid pulse therapy; however, treatment with rituximab was successful.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24827490     DOI: 10.2169/internalmedicine.53.1552

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Acquired Factor V Inhibitor.

Authors:  Daisuke Hirai; Yugo Yamashita; Nobutoyo Masunaga; Toshiaki Katsura; Masaharu Akao; Yoshiaki Okuno; Hiroshi Koyama
Journal:  Intern Med       Date:  2016-10-15       Impact factor: 1.271

2.  Acquired Factor V Inhibitors in a Patient with End-stage Renal Disease.

Authors:  Atsushi Kitazawa; Hideo Misawa; Katsuhiro Nagahori; Ryo Koda; Atsunori Yoshino; Shinya Kawamoto; Tetsuro Takeda
Journal:  Intern Med       Date:  2016-12-01       Impact factor: 1.271

3.  High Titer of Acquired Factor V Inhibitor Presenting with a Pseudo-deficiency of Multiple Coagulation Factors.

Authors:  Keiichi Nakata; Shuji Ueda; Hitomi Matsunaga; Fuka Mima; Hiroki Ueda; Aya Yoshioka; Sayoko Kaneko; Kazushi Maruo; Shayne Morris; Sayoko Yonemoto; Daisuke Hayashi; Naohiko Fujii; Hiroyuki Narahara; Yoshiaki Inui; Sumio Kawata
Journal:  Intern Med       Date:  2017-11-01       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.